logo-loader
viewWellesley Pharmaceuticals LLC

Wellesley Pharmaceuticals looks to raise $10 million for next round of clinical trials

Wellesley Pharmaceuticals CEO David Dill tells Proactive Investors the privately held company is aiming to treat the frequent need to urinate at night with its drug Nocturol. 

Dill says after the company received "compelling" data from its Phase 2 trials, it's hopeful to sign a licensing agreement with a big pharma to take over its drug. In the meantime, the company is raising capital to fund its next round of trials.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Chaarat Gold's Dusty Nicol talks increase to reserves at Tulkubash

Chaarat Gold Holdings Ltd's (LON:CGH) Dusty Nicol caught up with Proactive London's Andrew Scott to talk through the increase in reserves that's been announced for its Tulkubash project in Kyrgyz Republic. It follows last year's 20,000 metre drilling programme. Proven & probable...

2 days, 5 hours ago

2 min read